Search Result

Results for "

circulating lymphocytes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) CD44 (1) CXCR (1) Drug Derivative (1) GABA Receptor (2) Interleukin Related (1) IRAK (1) LPL Receptor (8) PROTACs (1) SphK (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (2) Inflammation/Immunology (14) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99459

Baminercept 2 Publications Verification BG 9924; TT-47	TNF Receptor CXCR	Inflammation/Immunology
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .

HY-150254A

SLB1122168 formic 1 Publications Verification	LPL Receptor	Inflammation/Immunology
SLB1122168 formic is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 formic inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 formic induces lymphopenia in circulating lymphocytes in mice and rats .

HY-124863A

(R)-AAL	SphK	Inflammation/Immunology
(R)-AAL is an immunomodulator. (R)-AAL decreases circulating T lymphocytes in rats, with an ID₅₀ value of 0.009 mg/kg. (R)-AAL is a substrate of sphingosine kinase (SphK), which catalyzes the phosphorylation of (R)-AAL .

HY-123801

MIDD0301 GL-II-93	GABA Receptor	Inflammation/Immunology
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABA_AR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases .

HY-175022

PROTAC IRAK4 degrader-13	PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective IRAK4 PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

HY-150254

SLB1122168	LPL Receptor	Inflammation/Immunology
SLB1122168 is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 induces lymphopenia in circulating lymphocytes in mice and rats .

HY-175984

S1P1 agonist 7	LPL Receptor	Inflammation/Immunology
S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC₅₀_{(G‑protein)} = 12.7 nM and EC₅₀_{(β‑arrestin)} = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .

HY-177700

Immunosuppressant-2	Others	Inflammation/Immunology
Immunosuppressant-2 (Example 21) is an orally active immunosuppressant. Immunosuppressant-2 significantly reduces the number of circulating lymphocytes. Immunosuppressant-2 can be used for research on various autoimmune diseases and organ transplant rejection .

HY-162655A

SLF80821178 hydrochloride	LPL Receptor	Inflammation/Immunology
SLF80821178 hydrochloride is an orally active inhibitor for sphingosine-1-phosphate transporter (Spns2), that inhibits the sphingosine-1-phosphate (S1P) release in HeLa with an IC₅₀ of 51 nM. SLF80821178 hydrochloride reduces the circulating lymphocyte without affecting plasma S1P levels in mice .

HY-149004A

SLF1081851 TFA	LPL Receptor	Inflammation/Immunology
SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system .

HY-119221A

AUY 954 hydrochloride	LPL Receptor	Neurological Disease
AUY 954 hydrochloride is a potent and selective sphingosine-1-phosphate (S1P(1)) receptor agonist, exhibiting significant immunomodulatory activity. AUY 954 hydrochloride induces a profound and reversible reduction of circulating lymphocytes upon oral administration. AUY 954 hydrochloride has demonstrated efficacy in prolonging cardiac allograft survival when used in combination with RAD001 in a stringent transplantation model. AUY 954 hydrochloride effectively prevents experimental autoimmune neuritis in rats, showcasing its therapeutic potential in autoimmune conditions.

HY-123801A

MIDD0301 sodium GL-II-93 sodium	GABA Receptor	Inflammation/Immunology
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABA_AR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases .

HY-182375A

SLB1122168 free base	LPL Receptor	Inflammation/Immunology Cancer
SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats .

HY-14371

LX2932	Drug Derivative LPL Receptor	Inflammation/Immunology
LX2932 is an orally active LX2931 (HY-14370) analogue and S1P/S1PR signaling axis modulator. LX2932 yields a dose-dependent decrease in circulating lymphocyte numbers. LX2932 improves collagen-induced arthritis .

HY-P992437

PF-03475952	CD44 Apoptosis	Inflammation/Immunology Cancer
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99459

Baminercept 2 Publications Verification BG 9924; TT-47	TNF Receptor CXCR	Inflammation/Immunology
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .

HY-P992437

PF-03475952	CD44 Apoptosis	Inflammation/Immunology Cancer
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.